Neurocrine Biosciences Stock News

Beyond analysts' top -and-bottom-line estimates for Neurocrine (NBIX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quar

Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some ad

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WHAT THE C@H?! provides a platform for  the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current research.

SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Stati

“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.

S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.

Artificial intelligence plays HubSpot and Arista Networks are among five stocks near buy points with big market news on tap.

Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. T

Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted

While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com

Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best op

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO , Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth q

Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.